Drug companies drop bid for ACCC approval of Revlimid patent settlement

Christian Dimitriadis 2022-07-29 11:44 am By Cat Fredenburgh

Please login to bookmark

Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au